Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alutard HDM SCIT biomarkers, long-term efficacy, and safety study in Chinese patients with allergic rhinitis
ChiCTR1800018602Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alutard-sq in allergic rhinitis (AR) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Specific IgE against 19 allergens including Der p and Der f, Der p-specific IgG4 and IgG1 and 4 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR1800018602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018602.